α-Galactosylceramide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.(In Vitro):Stimulation of activated Vα24+ NKT cell cultures with α-Galactosylceramide-pulsed monocyte-derived dendritic cells (Mo-DC) has antiproliferative activity against melanoma cells. Antiproliferative effects of Vα24+ NKT cells stimulated by α-Galactosylceramide-pulsed Mo-DCs via soluble mediators have antitumor activity against human melanoma. This effect is mainly due to the release of IFN-γ and, to a lesser extent, IL-12. Other cytokines, including IL-4 and IL-10, are released, but these cytokines have less antiproliferative effects .(In Vivo):α-Galactosylceramide treatment prevents spontaneous, oncogenic, or oncogene-induced primary tumor formation in mice. Consistent with a major role of IFN-γ in NKT cell-mediated tumor responses, the C-glycoside analog of α-Galactosylceramide, which preferentially stimulates IFN-γ production, was even more effective than α-galactose in preventing B16 melanoma metastasis. Ceramides are more effective . α-Galactosylceramide showed potent antitumor activity and stimulated lymphocyte proliferation (LP) in mouse allogeneic mixed lymphocyte reaction (MLR) .

α-GalCer; KRN7000

Others

Other Targets

GPR119

——

——

158021-47-7

858.3

C50H99NO9

>98% (HPLC)

——

CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC

——

(-20℃)

With Ice Pack

≥ 2 years